2022–2023 mpox outbreak in France

Outbreak of mpox in France

The 2022–2023 mpox outbreak in France is part of the global 2022–2023 mpox outbreak, which saw a significant increase in cases of mpox (formerly known as monkeypox) outside of its traditional endemic regions in Africa. The outbreak in France began in May 2022 and has been closely monitored by health authorities.

Background

Mpox is a viral disease caused by the monkeypox virus, a member of the Orthopoxvirus genus. It is similar to smallpox but generally less severe. The disease is characterized by a distinctive rash, fever, and swollen lymph nodes. Human-to-human transmission occurs through close contact with infected individuals or contaminated materials.

Outbreak in France

The first cases of mpox in France were reported in May 2022. The outbreak was part of a larger pattern of mpox cases emerging in non-endemic countries, primarily affecting men who have sex with men (MSM). The French health authorities, including Santé publique France, implemented measures to track and contain the spread of the virus.

Epidemiology

The outbreak in France was characterized by clusters of cases in urban areas, particularly in Paris and other major cities. The majority of cases were reported among young adult males, with a significant proportion identifying as MSM. The transmission was primarily through close physical contact, including sexual contact.

Clinical Presentation

Stages of monkeypox lesion development

Patients typically presented with fever, headache, muscle aches, and a rash that progressed through several stages, from macules to papules, vesicles, pustules, and finally scabs. The rash often began on the face and spread to other parts of the body, including the palms and soles.

Public Health Response

The French government, in collaboration with international health organizations, launched a public health campaign to raise awareness about mpox. This included information on symptoms, transmission, and prevention measures. Vaccination campaigns were also initiated, targeting high-risk groups.

Vaccination

The smallpox vaccine, which provides cross-protection against mpox, was offered to individuals at high risk of exposure. Vaccination centers were set up in major cities, and efforts were made to ensure equitable access to the vaccine.

Preventive Measures

Preventive measures included promoting safe sexual practices, encouraging individuals with symptoms to seek medical attention, and isolating confirmed cases to prevent further transmission. Public health messaging emphasized the importance of hygiene and avoiding close contact with infected individuals.

Impact

The mpox outbreak in France had significant social and economic impacts. Public health resources were mobilized to manage the outbreak, and there was increased public awareness of zoonotic diseases. The outbreak also highlighted the need for global cooperation in managing emerging infectious diseases.

Related pages

• Mpox
• 2022–2023 mpox outbreak
• Santé publique France
• Orthopoxvirus